Acadia pharmaceuticals initiates pivotal phase 3 study of carbetocin (acp-101) for the treatment of hyperphagia in prader-willi syndrome

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced the initiation of the phase 3 compass pws study evaluating the efficacy and safety of carbetocin nasal spray (acp-101) for the treatment of hyperphagia in prader-willi syndrome (pws). pws is a rare, neurobehavioral genetic disorder that is estimated to affect 8,000 to 10,000 patients in the united states.1-4 the most common symptom is hyperphagia, which is an unrelenting lack of satiety. other defining featur.
ACAD Ratings Summary
ACAD Quant Ranking